Cell to cell interaction is crucial for all multicellular organisms. There are robust biological interaction networks comprising protein-protein, gene-gene, gene-microRNA (miRNA) and parallel signaling as well as intracellular and distant cell communications for aggressive and therapyresistant cancers. 1, 2 The constant influx and efflux of biological material across nuclear and plasma membranes of cells controls the dynamic characteristics of such complex biological communication. There exist a number of additional transport mechanisms through which cells communicate with the outside environment (within its microenvironment and even at distant sites). Among them, vesicular transport, or ectosome and exosome-mediated transport, stands out. 3 Activated cells of various types are suggested to produce and shed membrane extracellular vesicles (EVs) into their surroundings. Some of these are also known as microparticles or ectosomes, whereas others are referred to as exosomes, depending on the properties and specific mechanisms of their generation. 4 Exosomes, unlike ectosomes, are membrane vesicles generated by endocytosis, endosome sorting into perinuclear multivesicular bodies (MVB) and exocytosis of MVBs. Exosomes appear to be different in size and composition from ectosomes. 4 Exosomes can be identified in the tumor microenvironment, and increasing evidence suggests that they play a significant role in facilitating tumorigenesis by modulating metastasis, angiogenesis and drug resistance. In addition, breast cancer exosomes derived from metastatic breast cancer cells, MDA-MB-231 and 4T1, revealed the higher enrichment in miRNAs compared to breast cancer exosomes derived from nonmetastatic breast cancer cells, MCF7. 5 The numbers of exosomes released by tumor cells and patients with cancer were also increased in their blood. 6, 7 Furthermore, although exosome-associated biomarkers have been well assessed in blood of cancer patients or in vitro cancer cell cultures, a critical evaluation for the in vivo relevance of the transfer and functional activity of exosomes between tumor cells has been challenged due to technical limitations in in vivo models. Recent finding by Zomer et al. however, showed a direct evidence for the EV exchange between tumor cells in living mice and thus leading to the transfer of functional biomarkers to alter cellular behavior. 8 They employed the Cre-LoxP system combined with highresolution intravital imaging to identify tumor cells that take up EVs in mice. This advanced technique provided the direct track of in vivo-released tumor EVs and the potential of functional activity of EV-associated biomaterials in living mice. The data showed that the in vivo-released EVs by highly metastatic human MDA-MB-231 breast cancer cells were taken up into the EVs of less malignant human T47D breast cancer cells, and thus leading to the change of metastatic behavior by phenocopy through extracellular vesicle exchange. 8 MiRNAs are a new class of small, nonprotein-encoding RNAs, which have been discovered in diverse organisms and are thought to regulate other genes' expression. 9 It is well known that miRNAs are involved in various biological processes, including stress resistance, cell differentiation and cell death. 10 They can also act as either oncogenes or tumor suppressors to regulate tumor progression and many contribute to tumor metastasis. 11, 12 Recent studies have demonstrated that miRNAs are secreted from various cells, including cancer cells, into body fluids such as blood, urine, breast milk and saliva, via exosomes. 6, 13, 14 Drug resistance is considered a major impediment in medical oncology. Although the different chemotherapy and endocrine regimens as well as targeted drugs have been commonly investigated, chemotherapy resistance is still a major obstacle to successful treatment. It is well known that there are two main types of resistance in cancer, which include the following: (1) inherent resistance, where insensitivity already exists before treatment, and (2) acquired resistance, which subsequently appears following the initial positive response. 15 At least some studies revealed that increasing sensitivity of breast cancer patients to anthracycline-based chemotherapy might be associated with miR-125 b through the deletion of chromosome 11q, a region containing the miR-125 b gene. 16 This finding suggested a possible connection between exosomal miRNA dysregulation and drug resistance in cancer. Herein, we will review reduced drug effectiveness, at least in part, caused by exosomal miRNAs.
Exosome-Derived miRNAs as Potential Tumor and Drug Resistance Markers
Tumor-derived exosomes, small (50-100 nm) membrane vesicles of endocytic origin, were initially investigated in the peripheral circulation of cancer patients in 1979. 17, 18 The upregulation of certain biomarkers in drug resistance and the increased presence in plasma and ascitic fluids of cancer patients have led investigators to propose a potential role for exosomes in diagnosis and biomarker analysis. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] The released exosomes contain a subset of both cellular mRNA and miRNA, which could be transferred to target cells in ovarian cancer patients. 30 In T cells, miRNA contained in tumor exosomes can suppress the mRNA for signal transduction components. 31 Released exosomes contain RNA populations, including miRNA; therefore, it is possible that this exosomal miRNA reflects the miRNA signature of the parental tumor. Thus, the association of miRNA with exosomes is significant in that exosomes can transfer cancer-specific molecules to other cells. 32, 33 Through this material transfer, exosomes have been indicated in contributing to tumor progression 34 as well as modification of the microenvironment 35 and the host. 36 Moreover, the variation of specific signaling pathways during carcinogenesis is also mediated by the miRNAs released by cancer cells 37 through the induction of angiogenesis, production of niches for metastasis 38, 39 and immune modulation. [40] [41] [42] Therefore, the packaging and export of miRNAs from cells and delivery of them to other cells may be significant processes for extracellular miRNAsignaling pathways and drug resistance (Fig. 1) . Additionally, increasing evidence has shown that exosomal miRNAs are positively related to the stage and degree of tumor progression. Cancer-derived miRNAs have also been identified in the blood of cancer patients compared to healthy controls. 6, 43 Exosome-derived miRNAs circulate in body fluids in a highly stable and cell-free form, probably due to their incorporation in exosomes, allowing their use as novel diagnostic and prognostic markers. 44 Thus, this will be useful for predicting both the clinical outcome of chemotherapy as well as the patient's risk of developing drug resistance. Taken together, there is a growing need for detecting critical molecular biomarkers, as shown in Table 1 .
Exosome-Derived miRNAs in Tumor Progression
There are two main pathways in which circulating miRNAs can be released from donor cells into body fluids. The first, most recently discovered pathway, occurs via the conjugation of miRNAs with RNA-binding proteins, such as Ago2. The complex can be released from the cell and circulates in body fluids. 86 The more investigated pathway occurs through the budding of membranes and creation of small membrane vesicles called exosomes that are secreted from cells. Then, exosomal miRNAs enable to exist and travel in plasma, serum and other fluids. Some of these miRNAs transported by exosomes can promote tumor progression through facilitating genetic material transfer in neighboring cells and inducing them to shuttle to distant tissues. [87] [88] [89] [90] [91] Through the use of exosomes, tumor cells can turn distant sites into primary tumor hosts. 92, 93 Previous study revealed that tumor secretion of the extracellular matrix proteoglycan versican induces a proinflammatory response by activating TLR2:TLR6 complexes in myeloid cells. 94 Fabbri et al.also reported that miRNAs from tumor cells bind to TLRs to induce pro-metastatic inflammatory responses. 95 In detail, they showed that miR-21 and miR-29a in exosomes secreted by tumor cells can bind to TLR8 (and TLR7) and active these receptors in immune cells, causing to TLR-mediated NF-OEB activation and secretion of pro-metastatic inflammatory cytokines. They also suggested that tumor-secreted miRNAs are associated with the pro-tumoral inflammatory process by activating the TLR8 response on immune cells. In addition, cancer-derived exosomal miRNAs may also bind as ligands to Toll-like receptors (TLRs) in surrounding immune cells. 95 Especially, Liu et al.identified a role of host lung epithelial cell TLR3 in promoting lung premetastatic niche formation via neutrophil recruitment. 96 snRNAs enriched in tumor exosomes activated TLR3 in alveolar type II epithelial cells, subsequently led to chemokine secretion and inducing neutrophil recruitment in the lung. High expression of TLR3 in adjacent tissues was intimately related to a high level of neutrophil infiltration, both of which predicted poor survival of the patients in human lung cancers. During tumor metastasis progression, the exosome-mediated transfer of miRNAs clustered in chromosome 19 can also be used as an immune regulator. 97 Therefore, secreted miRNAs are able to act as paracrine agonists of TLRs, and thus considered as key regulators of the tumor microenvironment. These actions of miRNAs are ultimately implicated in tumor-immune system interaction and are also significant in tumor growth, spread and metastasis. Exosomal miR-105 released from the breast cancer cell lines MCF-10 A and MDA-MB-231 reduced the level of ZO-1 gene expression in endothelial cells and promoted metastases to the lung and brain. 98 Exosomal miR-214, derived from the human microvascular endothelial cell line HMEC-1, promoted migration and angiogenesis in neighboring HMEC-1 cells. 99 MiR-6126 was the miRNA consistently overexpressed in all cancer exosomes released from three different paired ovarian cancer cell lines studied and further suggests that miR-6126 functions as a regulator of integrin b-1. 100 Ying et al. revealed that miR-222-3p transcripts are significantly higher in exosomes compared to their cells of origin. Moreover, miR-222-3p could be transferred between ovarian cancer cells and macrophages through exosomes secreted from tumor cells. 101 Zhang and colleagues recently also suggested that astrocyte-derived exosomal miR-19a reversibly downregulated PTEN expression in cancer cells, therefore increasing their CCL2 secretion and recruitment of myeloid cells to contribute to brain metastasis and tumor progression (Fig. 2) . 102 Collectively, these studies indicate that exosomal miRNAs play a crucial role in tumorigenesis, growth and metastasis (Table 2) .
Exosomes and Chemotherapeutic Resistance in Tumors
The development of chemotherapeutic resistance in tumor cells can be promoted by exosomes through a variety of mechanisms. Tumor-derived exosomes can transfer multidrug resistance (MDR)-associated proteins and miRNAs to target cells. 105, 112 P-glycoprotein (P-gp), a glycoprotein that is encoded by the ABCB1 gene in humans, is considered as drug efflux pump. 113 Because P-gp can efflux drugs into outside of the cell membrane, which is a process that requires the presence of two ATP-binding domains. Therefore, these domains are a defining characteristic of this family of ATPbinding cassette (ABC) transporters. 114 Subsequently, P-gp confers resistance by preventing sufficient accumulation of anticancer drugs within the cells. 115 To illustrate, Aldonza et al. revealed that the control of the TUBB3 response to ABCB1 genetic suppressors was a mechanism to reverse the profuse development of MDR in cancer cells. 116 Herein, our group established [117] [118] [119] [120] [121] that paclitaxel (PTX)-resistant cancer cells display ABCB1/ABCC1-associated cross-resistance to chemically different drugs. Through the FOXO3a-dependent regulation of ABCB1, which led in the accentuation of induced PTX resistance and encouraged multiplicity in acquired cross-resistance. Additionally, we found that secretome factors from PTX-resistant cancer cells with acquired crossresistance support a P-gp-dependent association in MDR development, which assisted the FOXO3a-mediated control of TUBB3 feedback. These results suggested that P-gp expression is highly associated with resistance. This work also reveals a rationale for manipulating TUBB3/b III -tubulin as a biomarker not just for PTX-resistant cancers but also for crossresistance to a broad class of drugs. In other studies, Zhou et al.
suggested that miR-105 is specifically secreted by MBC cells and may be transferred to endothelial cells via exosome secretion. 98 By employing deep sequencing analysis, they selected and profiled all small RNAs in the exosomes to identify the exosome-associated small RNAs which may induce migration. They measured the miR-105 levels in HMVECs treated with exosomes derived from MCF-10 A or MDA-MB-231 cells and found that an increase in the cellular level of mature miR-105 was observed in recipient HMVECs following the treatment with MBC (MDA-MB-231 metastatic breast cancer)-originated exosomes. These results suggested that MBC-secreted miR-105 might be transferred to endothelial cells via exosomes. A recent study also reported that suppression of miR-122 confers taxol resistance by upregulating Septin-9 in liver cancer. 122 The ERK-mediated XPO5 suppression reduces miR-122, subsequently increasing microtubule dynamics and leading to drug resistance or tumor development.
Previous studies also revealed that drug-resistant tumor cells are an abundant source of exosomes that may serve as paracrine modulators via the horizontal transfer of genetic cargo. 112, 123, 124 Because of this role, exosomes may have a defined set of miRNAs that transfer a resistance phenotype to sensitive cancer cells by altering cell growth and inducing anti-apoptosis programs. For example, through competing with endogenous RNA for exosomal miR-34 and miR-449, IncARSR is suggested as a mediator of sunitinib resistance in renal cell carcinoma. Thus, exosome-mediated transmission of IncARSR can confer resistance to sensitive cancer cells. 125 In epithelial ovarian cancer (EOC), Sun et al. suggested that miR-9 can mediate the downregulation of BRCA1 and impede DNA damage repair. Therefore, miR-9 may improve chemotherapeutic efficacy by increasing the sensitivity of cancer cells to DNA damage and may play a positive function in the treatment of ovarian cancer. 126 Importantly, the ability of exosomes shed by drug-resistant tumor cells to transfer the resistant phenotype to drug-sensitive cells has also been indicated as a significant mechanism for dissemination of drug resistance, mainly through transferring of drugefflux pumps and miRNAs. 127 The drugs and their metabolites can be encapsulated and exported by exosomes. 123, 128 Qu et al. also suggested that the resistance conferred by resistant exosomes was sustainable, possibly due to the triggering of an IncARSR-based signaling circuit in recipient cells. 125 Otherwise, via activation of STAT1-dependent antiviral and NOTCH3 signaling in cancer cells, transfer of fibroblastderived exosomes to breast cancer cells may also confer chemotherapy and radiation therapy resistance. 129 Exosomes may negatively affect chemotherapy treatment by shuttling out chemotherapeutic agents from target cancer cells. 130, 131 BM-MSC-derived exosomes induce multiple myeloma resistant to bortezomib through the activation of several survival relevant pathways. 132 Furthermore, vesicles isolated from the cell lines were shown to contain doxorubicin, a clinical chemotherapeutic to which tumors often develop chemotherapy resistance. Tumor-derived exosomes have also been shown to contain the platinum-based chemotherapeutic. Cisplatin is considered to potentially redirect the drug away from the nucleus where it would normally cause DNA damage, cell cycle arrest and apoptosis. 123, 130, 131 Recently, studies by Chen et al. also demonstrated that the ability of drug-resistant breast cancer (BCa) cells to transmit resistance capacity is potentially due to their release of exosomes, which could alter chemo-susceptibility in recipient sensitive cells by modulating drug-induced apoptosis. 133, 134 Other studies identified another method by which exosomes may also modulate chemotherapeutic resistance. Released exosomes from cancer cells might impede antibody and drug therapies by expressing cancer-derived cell surface proteins that sequester the compound away from the target cell. 135, 136 Additionally, exosomes have been suggested to reduce antibody dependent cell cytotoxicity by binding to tumor reactive antibodies. 132 These studies have revealed the significance of exosomal miRNAs in drug resistance and intercellular communication. 137 
Concluding Remarks
Drug resistance is considered an enormous obstacle in the treatment of cancer patients. As numerous underlying mechanisms are responsible for the development of drug resistance, EVs have emerged and attracted widespread attention as a novel therapeutic approach. This review highlights the role of exosomal miRNAs in chemotherapy resistance and tumor progression in different cancers. There is growing new evidence that more than one target or mechanism of tumor chemotherapy resistance has accumulated for certain drugs. MiRNAs might be more efficient in avoiding resistance or improving the effectiveness of malignant tumors to chemotherapy. Moreover, miRNAs may also be used as a potential biomarker to predict the response to chemotherapy and the survival in patients with malignant tumors. Therefore, combining miRNAs and traditional chemotherapy agents might provide a novel strategy in tumor drug resistance in the near future.
